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Abstract
Background:  Implementation of the World Health Organization's DOTS strategy (Directly
Observed Treatment Short-course therapy) can result in significant reduction in tuberculosis
incidence. We estimated potential costs and benefits of DOTS expansion in Haiti from the
government, and societal perspectives.
Methods: Using decision analysis incorporating multiple Markov processes (Markov modelling),
we compared expected tuberculosis morbidity, mortality and costs in Haiti with DOTS expansion
to reach all of the country, and achieve WHO benchmarks, or if the current situation did not
change. Probabilities of tuberculosis related outcomes were derived from the published literature.
Government health expenditures, patient and family costs were measured in direct surveys in Haiti
and expressed in 2003 US$.
Results: Starting in 2003, DOTS expansion in Haiti is anticipated to cost $4.2 million and result in
63,080 fewer tuberculosis cases, 53,120 fewer tuberculosis deaths, and net societal savings of $131
million, over 20 years. Current government spending for tuberculosis is high, relative to the per
capita income, and would be only slightly lower with DOTS. Societal savings would begin within 4
years, and would be substantial in all scenarios considered, including higher HIV seroprevalence or
drug resistance, unchanged incidence following DOTS expansion, or doubling of initial and ongoing
costs for DOTS expansion.
Conclusion: A modest investment for DOTS expansion in Haiti would provide considerable
humanitarian benefit by reducing tuberculosis-related morbidity, mortality and costs for patients
and their families. These benefits, together with projected minimal Haitian government savings,
argue strongly for donor support for DOTS expansion.
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Background
Between 1997 and 2002 the incidence of active TB
increased in most low and middle income countries [1].
This occurred despite the availability of adequate tools for
diagnosis and treatment, and an effective TB control strat-
egy – which has been labelled DOTS. This strategy, origi-
nally developed in sub-Saharan Africa, is being promoted
by the World Health Organisation (WHO) [2] because it
is feasible in high-burden settings [3], cost-effective even
in low income countries [4], and can result in substantial
reduction in TB incidence [5].
However, between $290 – $500 million (US) is required
annually for the additional training, equipment and infra-
structure needed to implement and maintain DOTS in all
low and middle income countries [6,7]. As a result DOTS
expansion has lagged considerably behind WHO targets
[8].
In the America's, Haiti is the poorest country [9], with the
highest incidence of smear positive pulmonary TB (138/
100,000 in 2002) [8] and HIV seroprevalence (4.5% in
2002) [10]. In 2002 the WHO estimated that only 37% of
the population had access to DOTS programmes [11],
only 49% of all smear positive cases were diagnosed, and
only 71% of those diagnosed were successfully treated [8].
We have compared projected TB related outcomes and
costs if the current control programme is maintained (sta-
tus quo), or if DOTS is expanded to reach WHO bench-
marks, for 100% of the population in Haiti.
Methods
General description of model and the two strategies 
compared
We developed a decision analysis model, incorporating
multiple Markov processes, (Markov modelling) using
Tree-Age Pro Release 6.0, (Tree-age Inc., Williamstown,
MA). This model calculated the probability of TB-related
events expected to result over 20 years, starting in 2003,
from two alternate strategies for TB control. These proba-
bilities were calculated for a hypothetical fixed cohort
with the age structure, socio-demographic and health
characteristics and size of the population of Haiti in 2002.
The information on the population of Haiti, summarized
in Table 1, was taken from publicly accessible information
provided by international agencies including the World
Bank, WHO, and the United Nations Program on AIDS
(UNAIDS) [8-10].
The strategies compared were to continue the present
national TB control programme (status quo), or DOTS
expansion. With the status quo strategy there would be no
change over the 20 year time frame of the analysis, from
January 2003 levels of: DOTS coverage [11], case finding
[8], treatment outcomes [8], incidence of smear positive
TB [8], prevalence of initial TB drug resistance [12,13],
and HIV seroprevalence [10]. Since incidence of disease
did not change with the status quo, risk of TB infection
[14], and LTBI prevalence also remained unchanged
throughout the period of analysis. Current levels of DOTS
coverage have been achieved with assistance from foreign
donors – hence we implicitly accounted for current for-
eign assistance. However, we did not explicitly add in
these expenditures, since they would have been added to
both strategies, making both more expensive, but without
changing the differences between them.
With DOTS expansion, we assumed that DOTS would be
expanded from the level of coverage in January 2003,
(Year 1) [11], to reach 100% of government health facili-
ties by the end of Year 3. Case detection would increase
from current WHO estimated levels [8] to 70%, and treat-
ment success (cure and treatment completion) to 85% –
the WHO targets [3], although treatment failure and TB
mortality would not change [8]. Rates of initial drug
resistance [12,13] and HIV prevalence [10] would not
change with DOTS over the full 20 years. DOTS imple-
mentation would halve pre-diagnostic health system visits
[15,16], and health system delays [17-19], although
patient delays would not change. Hospitalisation dura-
tion would decrease by two-thirds [15,16]. The number of
patients investigated for each new case of TB diagnosed
would increase from 4 to 16 [20]. Retreatment failures
(multi-drug resistant TB) would be treated with second
line drugs obtained from the Green Light Committee [21]
with 48% cure, and 12% mortality [22]. Most importantly
DOTS expansion was assumed to result in a 6% annual
decline in incidence, as described in Peru following
national DOTS implementation [5]. This would produce
corresponding reductions in the risk, and prevalence of TB
infection [14].
Health states and transitional probabilities (see Figure 1)
At the start of Year 1 (assumed to be 2003), cohort mem-
bers were considered to be in one of five TB-related states,
and one of three HIV-related states. The TB-related states
were: 1) no tuberculosis infection; 2) recent latent tuber-
culosis infection (LTBI) – acquired within 2 years; and, 3)
long-standing LTBI – acquired more than 2 years ago; 4)
active tuberculosis; and, 5) treated, or spontaneously
resolved active TB. States 2–5 were further sub-classified
into 3 groups: drug-sensitive, single-drug resistant, or
multi-drug resistant TB – with likelihood based on surveys
of drug resistance in Haitian populations [12,13]. The
proportion with recent or long-standing LTBI was calcu-
lated based on the age structure of the population [23],
and incidence of smear-positive active disease [8], using
the Styblo formula [14].BMC Public Health 2006, 6:209 http://www.biomedcentral.com/1471-2458/6/209
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Key pathogenetic model assumptions regarding reactiva-
tion and cure rates for HIV-negative and HIV-positive
individuals, summarized in Table 2, were based on pub-
lished cohort studies and randomized trials. In HIV nega-
tive persons, active TB would develop in the first two years
after new TB infection in 5% of the population [24]. In
other studies the risk of disease in the first two years after
new TB infection ranged from 4% [25] to 10% [26]. Given
the 80% protective effect afforded by previous latent TB
infection in HIV uninfected persons [27], re-infection
would be followed by a 1% risk of active TB in the first two
years. In latently infected persons risk would be 0.1%
annually after the first two years – based on prospective
follow-up of two tuberculin positive cohorts – of young
military recruits [28], and Vietnamese refugees [29].
The probability of transfer out and default varied by strat-
egy. We assumed that the treatment outcome of "trans-
ferred-out" was equivalent to default [30]. For individuals
who defaulted from therapy we assumed an overall cure
rate of 62%, calculated from the proportion of defaulters
after different lengths of therapy [31], and cure rates in
randomised trials of regimens of 3 or 4 months duration
[32-34].
The HIV-related states were: 1) no HIV infection; 2) early
HIV, defined as having no clinical manifestations; or, 3)
late HIV infection – defined as clinical AIDS. HIV-related
survival and annual rates of transition from early to late
HIV states were based on a Ugandan cohort [35]. Proba-
bility of acquiring HIV infection was the same in both
strategies. Annual risk of HIV infection was estimated to
be 0.49% – calculated from the general population preva-
lence [10] divided by the average years of survival in a
low-income setting [35] (and thus assumed to be uniform
for the entire population). We assumed no consequence
of HIV re-infection.
The same model was used for HIV infected or uninfected.
The proportion of HIV infected persons entering the
model was 0.045 – corresponding to the estimated sero-
prevalence in Haiti in 2002 (10). Every year, 0.5% of the
uninfected population could acquire new HIV infection,
thus changing from an HIV uninfected to an HIV infected
Table 1: Summary of key input data for Haiti in 2002(All costs in US dollars)
EPIDEMIOLOGIC/PROGRAMME DATA HAITI REFERENCE/SOURCE
Population (2002) 8.3 million [9]
Gross National Income annual per capita (US$) $ 440 [9]
Life expectancy at birth 52.0 [9]
All cause mortality Age specific [44]
Incidence new smear positive TB per 100,000 (2001) 138 [8]
Annual risk of TB infection (ARI) 2.26% Calculated from [14] and [8]
Prevalence of LTBI at age 20 41% Calculated from [14]
Likelihood of diagnosis and treatment of LTBI 1% [59] *
Completion of LTBI Treatment 67% [60]
Efficacy of 9 INH – INH Sensitive 90% [61]
INH Resistant 0 [62]
Prevalence of HIV infection – 2002 4.5% [10]
Incidence of HIV infection 0.46%/year Calculated from [35]
DOTS Coverage – 2002 37% [11]
Case detection rate – 2001 49% [8]
Drug Resistance
Single drug resistance 20% (11%-31%) [12]
Multi drug resistance (HR) 0.3% (0–4%) [12;63]
Treatment outcomes New cases – 2001 Overall [8] DOTS areas (NTP) Non-DOTS
Cure/complete 71% 85% 63%
Default/transfer/not evaluated 23% 9% 31%
Die 5% 5% 5%
Fail 1% 1% 1%
Outcomes Re-treatment cases – 2001 Overall [8] DOTS areas (NTP) Non-DOTS
Cure/complete 54% 80% 39%
Default/transfer/not evaluated 29% 4% 44%
Die 8% 8% 8%
Fail 8% 8% 8%
Notes:
* – This assumes only dually infected (HIV and TB infection) whose HIV infection is detected and are tuberculin tested at a limited number of 
screening centres will be treated.
NTP – data on treatment outcomes in areas with DOTS, from cohort reports to National TB programmeBMC Public Health 2006, 6:209 http://www.biomedcentral.com/1471-2458/6/209
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state. The major difference in the model for HIV infected
and uninfected was in regard to the probability of devel-
opment of active TB following TB infection and mortality
– without TB, or during and after treatment for active TB.
The risk of active TB in persons with LTBI, and HIV infec-
tion has been studied in a number of settings. We could
find only one study that categorized cohort members into
the states of new or old TB infection and early or late HIV
[36]. This was used for the base case estimate of 3.4%
annual risk of active TB disease in persons with long-
standing LTBI and HIV infection.
We could not find published estimates of risk of disease
following new TB infection in HIV infected individuals.
Therefore we extrapolated from HIV negative persons, in
whom the risk of development of active TB following new
LTBI infection is 20–50 times higher than with long-
standing LTBI [24-26]. Given the 3.4% annual risk of
active TB in early HIV infection and long-standing LTBI
[36], we assumed the risk of TB disease would be 10 times
higher, or 34% per year during the first two years follow-
ing new TB infection.
Response to treatment of TB disease was not affected by
HIV infection. HIV-infected individuals with smear posi-
tive active TB were assumed to have no chance of sponta-
neous cure – hence 100% mortality without treatment. If
treated, TB mortality would be 2.25 times higher during
treatment [37-39], and 2.2 times higher after treatment
[3,40,41]. Mortality from active TB disease with MDR
strains would be 100% [42,43].
Model calculations
Beginning in 2003 (Year 1), the model determined the
proportion of the cohort developing smear positive active
TB, dying from TB, or dying from other causes in each year
for 20 successive years. The risk of death from other causes
was derived from the age distribution and HIV sero-prev-
alence of the cohort, and country-specific life tables pub-
lished by WHO [44]. The probability of TB related
outcomes depended on cohort members' TB and HIV
related states (infected or not, and new or old), as detailed
above, and summarized in Table 2. Clinical outcomes
also varied according to whether each TB related state was
diagnosed and treated.
Sample decision analysis tree for Haitian adult, initially without TB infection, nor HIV infection who acquires new TB infection Figure 1
Sample decision analysis tree for Haitian adult, initially without TB infection, nor HIV infection who acquires new TB infection.
* Probability of acquiring TB infection is key variable that falls over time as 
DOTS expansion occurs and remains unchanged as status quo. Probability of
HIV infection does not change with DOTS, nor over 20 years
‡ The letter “p” refers to probability. For example pdieother = probability of
dying from other cause
** Latent infection can be drug sensitive, single, or multiple-drug resistant – but
this does not actually affect  health state unless active TB develops
†  Probability of diagnosis higher with DOTS (70%) than non DOTS
†† States that are entered in subsequent cycles are not shown in this figure
‡‡Probability of death, default, fail or cure (treatment outcomes) different with
DOTS than non DOTS
Haitian adult
HIV uninfected,
TB uninfected
Terminal node
Cycle back into Recent LTBI for 1 year and
then into old LTBI if no reactivation occurs
Same decision node as shown for drug
sensitive, however probabilities of 
failure or cure are different
Enters into
Recent
LTBI state
Pundiagnosed
DOTS
diagnosed
Single Drug Resistant
pSDR
Multi Drug Resistant
pMDR
premaininfectedwLTBI
developed active TB
die other
pdieother‡ Acquires TB 
infection *
(could also acquire
HIV infection, but
details not shown in
this diagram)
remain infected with LTBI**
Cycle into “active TB” state ††
Cycle into “spontaneously resolved TB” state ††
Terminal node
Terminal node
Cycle into “cured TB”
state ††
Cycle into “active TB”
state ††
Cycle into “cured TB” state ††
pongoingillness
spon resolve
die
pdieundiagnosed
die
pdieDOTS ‡‡
not cured
pdefaultnocure
default
pdefaultDOTS ‡‡
cure
Pcure DOTS ‡‡
retreatment
no retreatment
pnoretreatment
failure
pfailDOTS ‡‡
ongoing illness
undiagnosed
psponresolve
Drug Sensitive
pDS
cured
pdefaultcure
Pdiagnosed
DOTS†
Probability of developing active
TB not affected by DOTS but
is affected by HIV status
pactiveTBHIVuninfected Cycle into “re-treatment
active TB” state †† pretreatment
Cycle into “no re-
treatment active TB”
state ††BMC Public Health 2006, 6:209 http://www.biomedcentral.com/1471-2458/6/209
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Table 2: Probabilities of outcomes with different TB and HIV health states
PATHOGENETIC FACTOR BASE RANGE REFERENCE
Reactivation from latent TB infection
Present more than 2 years ("long-standing LTBI")*
HIV uninfected 0.1%/year 0.1% – 0.2%/year [28;29]
HIV infected – asymptomatic 3.4%/year 3.4% – 8.7% [36;64;65]
HIV infected – AIDS 33%/year 33% – 67% [36]
Within 2 years of new TB infection ("recent LTBI")
HIV uninfected 5% 2% – 15% [24;66]
HIV infected – asymptomatic 33% 33% – 100% Extrapolated
HIV infected – AIDS 100% 50% – 100% [42;43;67–69]
Within 2 years following re-infection
HIV Uninfected 1% [27;70]*
HIV infected 33% or 100% Assumption
Outcomes of untreated smear positive TB
Mortality – 1 year, & 2 years 33%, & 50% From [71]
Spontaneous remission 25% [72]
Relapse after spontaneous remission 2.5%/year 1.3% – 2.5%/year [72;73]
Outcomes of treated smear positive TB
Relapse after cure (total over next 2 years) 3.0% 1.5% – 5% [74–78]
Cure rate if default (SDR or drug sensitive) ** 62.4% [31–34]
Effect of drug sensitivity or treatment outcomes
Relative risk of failure/if single drug resistant 2.0 [79]
Relative risk of failure/if multi-drug resistant 10.5 [79]
Relative risk of death/if single drug resistant 1.0 [79]
Relative risk of death/if multi-drug resistant 4.5 [79]
If MDR – Probability of cure with treatment 48% 48%-73% [22;80]
- Probability of death with treatment 12% 12%-26% [22;80]
HIV Infected and TB
Average duration of HIV infection – Total 9.8 years 7.3–9.8 [35;81]
- Time spent in HIV asymptomatic state 9.0 years [35]
Annual risk of progression of asymptomatic HIV to AIDS 7% 7%-9% [35;81]
Annual risk of death from HIV: HIV asymptomatic state 4.6% [35]
Annual risk of death from HIV: AIDS 22% [35]
Effect of prior active TB on relative risk of death from HIV 2.2 (2.2 – 4.0) [3;40;41]
Effect of HIV infection on relative risk of death during TB treatment (drug sensitive or 
single drug resistance)
2.25 [37–39;82]
Relapse after successful TB treatment (cured) 3.1% 3.1% – 6.4% [83–85]
* Assume that rate of reactivation more than two years after TB infection is the same whether it is after a first infection, or after re-infection.
** Transfer out considered equivalent to default [30]. Overall cure rate if default based on timing of default (from [31]), and cure rates from trials of 
very short course treatment [32–34].
Cohort members who survived to the end of each year in
the model, entered the following year of the simulation.
Health states at the beginning of each year depended on
the events during the preceding year. As a (simplified)
example, some members of the cohort entered Year 1 in
the health state of no TB infection. If they survived Year 1
without acquiring TB or HIV infection they entered Year 2
in the same state. However if they acquired new TB infec-
tion during Year 1, they entered Year 2 in the "new TB
infection" state. During Year 2, they could develop active
TB (with probability as shown in Table 2), die from other
causes, or remain with new TB infection (entering Year 3
with this health state). If they developed active TB they
could be diagnosed and treated, or remain undiagnosed.
Likelihood of diagnosis, and treatment outcomes varied
according to the strategy being analyzed (see Table 1), and
underlying drug resistance. The probability of having pan-
sensitive, single drug resistant, or multi-drug resistant
underlying strains, was determined from two surveys of
initial drug resistance in Haitian TB patients [12,13]. If
undiagnosed they could die of TB (probability in Table 2)
or other causes (from Life Tables), or survive and enter
Year 3 with undiagnosed TB disease.
The model generated a single value for the cumulative
proportion of the cohort that developed active TB, died of
TB, or died of other causes throughout the 20 years for
each strategy. This was then multiplied by the size of the
population to generate expected total number of persons
developing each outcome over the period of analysis.BMC Public Health 2006, 6:209 http://www.biomedcentral.com/1471-2458/6/209
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Costs
Costs were estimated from societal, and governmental
perspectives [45]. Costs modelled from the government
perspective included TB-related health care costs for gov-
ernments and health care providers, plus costs for DOTS
implementation, maintenance, and drug costs. TB related
costs from the societal perspective included government
costs, plus patients' and families' out-of-pocket expendi-
tures, lost wages (including time caring for ill family
members), plus productivity losses resulting from disabil-
ity and death [45]. All costs were expressed in 2003 US
dollars, and all future expenditures and outcomes were
discounted 3% annually [46].
A questionnaire regarding the household impact of fatal
adult illness [47] was adapted, pre-tested in Montreal, and
translated into French and Creole – to measure out-of-
pocket costs and lost income for patients and families for
pre-diagnostic, hospitalisation, treatment and follow-up
visits. This was administered by trained interviewers to 84
consenting adults in their second and third months of
therapy for new smear positive pulmonary TB, at the same
facilities where health system costs were ascertained. To
estimate government TB expenditures, we surveyed
administrators of 8 rural, and 8 urban health facilities,
including 3 TB sanatoria, 5 general hospitals, 5 general
clinics, and 3 TB dispensaries. This study was approved by
the Institutional Review Board of McGill University, and
the National TB control programme of Haiti.
Costs for DOTS implementation and maintenance were
based on a DOTS expansion project in Ecuador [48], pro-
rated to Haiti, based on their respective per capita gross
national incomes [49]. Drug costs were calculated from
the model estimates of number of new and retreatment
cases, and unit costs from the Global Drug Facility [50].
Patients with active TB were assumed to be 50% disabled
(productivity loss) from symptom onset until diagnosis,
unable to work while hospitalised, and 50% disabled for
the remainder of the first two months of treatment [17-
19]. Patients who were not diagnosed or who failed treat-
ment were assumed to have 50% disability throughout
their illness. Productivity loss from death in HIV unin-
fected was estimated as per capita annual income [9]
times the number of years remaining in the model, with
appropriate discounting [46]. For HIV infected the pro-
ductivity loss was estimated based on the number of years
they would be anticipated to survive after development of
active TB based on total survival of 9.8 years (35) and the
number of years they had survived with HIV infection
before developing active TB.
Sensitivity analyses
We conducted extensive one-way sensitivity and thresh-
old analyses, to assess the robustness of our findings to
variations in key assumptions. Each parameter was varied
individually, except for pathogenetic parameters that were
based on well characterized, carefully studied cohorts. We
examined the effect of varying rates of decline in tubercu-
losis incidence following DOTS expansion, increasing
HIV seroprevalence and drug resistance, case detection
rate, and higher costs of DOTS implementation, mainte-
nance and drugs. Where possible, sensitivity analyses
reflected ranges from the published literature. If these
were not available, other variations were used such as
halving or doubling costs. We also modelled composite
"best case" and "worst case" scenarios, based on combina-
tions of favourable and unfavourable assumptions for
influential model assumptions – reflecting findings of the
initial one-way sensitivity analyses.
Results
As shown in Table 3, current government expenditures
averaged $432 per TB patient, of which hospital services
accounted for 64%, and TB drugs less than 5%. For the 84
TB patients and families surveyed, total TB related out-of-
pocket expenses, and lost income averaged $334 – equiv-
alent to 76% of average per capita income of Haitians in
2002. Of 34 patients who could compare earnings before
onset of TB and at the time of the survey, 9 (26%) had a
significant drop in income (average 65%), while only one
(3%) reported increased income.
With the status quo strategy, 226,590 TB cases, and
107,070 TB-related deaths are projected to occur in Haiti
over 20 years (Table 4). This morbidity and mortality will
result in total societal costs of $378 million, including
government costs of $59 million. The DOTS expansion
strategy is projected to avert 63,080 TB cases, prevent
53,120 TB deaths, and result in societal savings of $131
million, over 20 years. Of the societal savings, 73% will
result from deaths averted, and 20%, or approximately
$26 million would reflect savings for patients and their
families.
We project a reduction in government expenditures for
hospital services from $38 million to $22 million. How-
ever these savings would be offset by the need for initial
investment for DOTS expansion, plus increased recurrent
government expenditures for smear microscopy, directly
observed treatment, multi-drug resistant (MDR) TB treat-
ment, supervision, training, and quality control. As a
result, net government savings are projected to be only $4
million over the full 20 years.
The substantial societal savings with DOTS expansion was
robust in all sensitivity analyses, including doubling the
prevalence of drug resistance, or doubling the costs for ini-
tial DOTS expansion, for TB drugs, or for ongoing super-
vision and training (Table 5). Of note – even if theBMC Public Health 2006, 6:209 http://www.biomedcentral.com/1471-2458/6/209
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incidence did not decline at all under DOTS expansion,
DOTS is still predicted to result in substantial society sav-
ings through reduced mortality and reduced costs for
patients and their families. However, government savings
were much more susceptible to changes in assumptions-
reflecting the very modest government savings in the base
case analysis. Haitian government savings would be sig-
nificant only if foreign donors supported the costs for
DOTS expansion.
As seen in Figure 2, the DOTS expansion strategy would
begin to result in societal savings within 4 years, although
government savings would only begin after 15 years. A
small increase in HIV sero-prevalence would result in a
Table 3: Summary of health system and patient costs in Haiti
MEAN (SD) SOURCE
Pre-Diagnosis
Total Time (onset of symptoms to diagnosis) 4.4 months (3.5 months) PCQ
Number of Visits 4.7 (7.2) PCQ
Cost to health system for visits (total) $16.31
Lab costs (per patient – 3AFB smears) $4.46 (--) [53]
Patients out-of-pocket: for visits (total) $40.55 ($138) PCQ
Miscellaneous $22.87 ($116.85) PCQ
Lost income for patient/family: for visits $6.19* PCQ
Miscellaneous $61.71* PCQ
Hospitalization
N (%) hospitalized 47 (56%)
Average length of stay (for all 84) 21.3 days (27.2) PCQ
Health system costs (per patient) $321.00 (--) HFQ
Patient out-of-pocket (per hospitalization) $92.69 ($323.41) PCQ
Lost income for patients and family $29.40* ($44.37) PCQ
Direct Observation of Treatment (DOT)
Number of visits 75 -- NTP
N (%) on DOT 43 (51%) --
Health system costs: for DOT (total) $48.75 -- HFQ
For drug costs (new case) $20.93 -- **
Patient out-of-pocket expenses (total) $56.25 ($141.00) PCQ
Lost income for patient and family $20.40* ($25.50) PCQ
Follow-up (Medical Check Up)
Number of visits 6 -- NTP
Health system costs (total) $20.82 -- HFQ
Patient out-of-pocket expenses $1.88 ($11.65) PCQ
Lost income for patient and family $2.35* ($3.67) PCQ
Total cost per TB patient treated
Health system $432.27
Patient and Family: out-of-pocket costs $214.24
Lost Income $120.05
Total patients and families $334.29
Notes:
* Income = $0.17 (US) per hour based on average per capita GNI ($440) (reference 9)/2496 hours (= 48 hours × 52 weeks)
PCQ = Patient cost questionnaire
HFQ = Health facility questionnaire
NTP = National TB programme guidelines
** = Prices for drugs in DOTS areas from [86], and 1.4 times higher in non-DOTS areas [15;16]BMC Public Health 2006, 6:209 http://www.biomedcentral.com/1471-2458/6/209
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substantial increase in the number of TB cases, deaths,
and TB-related societal costs (Figure 3), although savings
with DOTS would be greater. As seen in Figure 4, societal
savings would increase by more than $4 million for every
5% increase in case detection. This reflects the lower mor-
tality that would result when more smear positive cases
are detected and treated.
Discussion
We project that DOTS expansion in Haiti, to reach WHO
targets, would cost an initial $4.2 million and result in
28% reduction in TB cases, 49% reduction in mortality
and net societal savings of $131 million over 20 years.
However, we project that the Haitian government would
have to make significant initial investment and only begin
to achieve savings after 15 years. Taken together, these
Table 4: Projected cumulative TB incidence, related mortality, and costs with two strategies for TB control in Haiti: base case analysis
TOTAL COSTS (SAVINGS)
($US MILLIONS)
PERSPECTIVE
TOTAL TB CASES TOTAL TB DEATHS SOCIETAL GOVERNMENT
AFTER ONLY 5 YEARS
- Status Quo 64,740 25,730 $77 $16
- DOTS expansion 59,760 19,090 $70 $21
- Cases or deaths averted and added costs or
(net savings) with DOTS
4,980 6,640 ($7) $5
AFTER 10 YEARS
- Status Quo 125,330 54,780 $173 $32
- DOTS expansion 103,750 34,030 $134 $35
- Cases or deaths averted and added costs or
(net savings) with DOTS
21,580 20,750 ($39) $3
Over Full 20 Years
- Status Quo 226,590 107,070 $378 $59
- DOTS expansion 163,510 53,950 $248 $55
- Cases or deaths averted and (net savings) with DOTS 63,080 53,120 ($131) ($4)
Table 5: Sensitivity analysis for projected savings over 20 years with DOTS expansion in Haiti
SAVINGS in $US MILLIONS
WITH DOTS EXPANSION *
PERSPECTIVE
PARAMETER VARIED CHANGE NEW VALUE SOCIETAL GOVERNMENT
Base Case (from Table 4) Base Base ($131) ($4)
Initial DOTS investment Double $8.4 million total ($126) ($0)
Annual DOTS maintenance Double $722,000 per year ($128) ($1)
Annual DOTS maintenance + cost of TB 
drugs
Double both $847,900 per year ($128) ($1)
Foreign Donor Pays: Initial + annual + TB 
drugs
Eliminate all three $8.44 million + $847,000 
per year
($138) ($11)
Change average duration of hospitalization Decrease with DOTS, 
increase with Non-DOTS
3 days – DOTS 60 days 
non-DOTS
($165) ($29)
Single (SDR) and Multi (MDR) Drug 
resistance
Double prevalence of drug 
resistance
SDR : 40% MDR : 0.6% ($131) ($4)
Impact of DOTS expansion on TB 
incidence in subsequent years
None
1/3 of base
2/3 of base
0% annual decline
2% annual decline
4% annual decline
($61)
($88)
($111)
$ 14 *
$ 7*
$ 1*
Notes:
* A number in parentheses indicates net societal or government savings, while a number not in parentheses indicates a net increased cost with 
DOTS expansion,.BMC Public Health 2006, 6:209 http://www.biomedcentral.com/1471-2458/6/209
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findings should provide a powerful argument for foreign
donors to support initial DOTS expansion in Haiti.
Several findings deserve comment. We have projected sav-
ings totalling $26 million for patients and their families
from DOTS expansion. Among the patients surveyed,
direct out-of-pocket expenditures and lost income repre-
sented 49% and 27% respectively of the average yearly per
capita income in Haiti. And patients surveyed also
reported a substantial drop in income at the time of the
survey compared to prior to onset of their illness. Savings
are anticipated with DOTS expansion, because the decen-
tralisation of diagnostic and treatment services should
result in faster diagnosis [17-19], reduced hospitalisation
[15,16], and reduced out-of-pocket expenses for treat-
ment and follow-up. Such projected benefits should make
DOTS expansion a top priority for donors supporting the
Millennium Development goal of poverty reduction [51].
The estimated current government expenditures of $432
per TB patient were surprisingly high – very close to the
average per capita income of $440 [9]. We project poten-
tial savings from reduced hospitalization, but these will
only be realized if hospital expenditures are actually
reduced (i.e., by closing beds and reducing staffing). As
well any such savings will be offset by increased expendi-
tures for directly observed treatment, and staff supervi-
sion, quality control and training. These costly activities
are essential for maintenance of a proper DOTS pro-
gramme [52], but are not necessarily components of TB
control programmes prior to DOTS expansion. Therefore
new positions must be created, and new workers found
with different knowledge and skills – a formidable chal-
lenge in many low-income countries. And, immediate
government expenditures are required, while savings will
only begin after 15 years. As Harold Wilson pointed out "a
week is a long time in politics"; most governments will
consider 15 years far too long to wait for a payback.
Hence, there is little immediate incentive for the Haitian
government to implement DOTS.
Another important component of projected government
expenditures following DOTS expansion will be lab costs,
totalling $9.6 million, or 17% of all TB related govern-
ment expenditures over 20 years. This reflects the high
labour costs for smear microscopy [53], which can take up
to 20 minutes of technician time per specimen [52]. In
Peru only 2% of TB suspects investigated are smear posi-
tive [54], meaning that up to 150 negative smears are
examined for each new case found. If treatment success
exceeds 85%, enhanced case detection is essential for the
long-term epidemiologic impact of DOTS, given the high
mortality, and contagiousness of undiagnosed cases.
However, given our projections of substantial expendi-
tures for smear microscopy, a high priority should be
Effect of changes in the case detection rate with DOTS  expansion on total societal savings over 20 years in Haiti Figure 4
Effect of changes in the case detection rate with DOTS 
expansion on total societal savings over 20 years in Haiti.
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given to replacing this labour intensive cornerstone of the
DOTS strategy.
This study is novel in that we conducted direct surveys to
ascertain costs of health facilities, the national TB pro-
gramme, and TB patients themselves. In this impover-
ished nation, patient and government expenditures for TB
are remarkably high. We combined this direct data gather-
ing with estimates of disability, costs for DOTS expansion,
and TB drugs from published experience elsewhere. Addi-
tional strengths include the complex decision analysis
model which incorporated five TB related health states
(with one of three underlying TB drug resistance states)
and three HIV related health states within the same
model. As well published estimates of risk of TB and HIV
infection, HIV progression, development and outcomes
of active TB, and mortality were used.
However, there were a number of important potential
limitations of this decision analysis. These included our
assumptions regarding impact of DOTS on incidence,
prevalence of HIV and drug resistance, stability of the
population, methods of calculation of annual risk of
infection, and costs for DOTS expansion. The assumption
that incidence would decline 6% annually following
DOTS expansion was based on observations in Peru after
nationwide DOTS implementation [5]. This rate of
decline is midway between two recent estimates – of 4.3%
annually observed with DOTS in China [55], and 7.5%
annually predicted for countries achieving WHO targets
[56]. And, in sensitivity analyses, societal savings were still
substantial even with the extreme assumption of no
change in incidence at all. We calculated annual risk of
new TB infection from estimated incidence using the Sty-
blo formula [14] – which has been criticized [57]. How-
ever, the same formula was applied to both strategies in
all years, so inaccuracies in the estimate of infection rates
would have been similar for both strategies. We may have
over-estimated societal savings because we did not
account for other illnesses causing health care costs or dis-
ability among those who survived with active TB. How-
ever these potential costs should be relatively low since
the average age of the patients with active TB in Haiti was
34 so that even those with the most gains in survival
would only be 54 by the end of 20 years. As well we did
account for mortality from HIV infection (from published
studies), and all other causes (from WHO life tables for
the general population of Haiti). Thus the most important
future societal costs among the added survivors with
DOTS, were accounted for in the analysis.
Costs for DOTS expansion are difficult to estimate as there
is little published experience to date. For this analysis,
costs for expansion were based on published experience
in Ecuador [48]. Given the social, economic, and epidemi-
ologic differences between Ecuador and Haiti, these esti-
mates may not be considered valid for Haiti. However
these estimated costs were higher than actual costs
incurred for a DOTS expansion project in India [58] where
the economic situation is very similar to Haiti [9].
A very important limitation of our analysis is the assump-
tion that basic government health services would con-
tinue to operate. Therefore we only accounted for the
additional costs of DOTS expansion and maintenance.
Continued basic government health services in Haiti,
depends upon political stability, which is among the
worst in the Americas. This problem has contributed to
the current problems of the national TB control pro-
gramme. But, the DOTS strategy has been successfully
implemented and maintained amidst major civil conflicts
in Mozambique and Nicaragua. Therefore we believe our
findings should not be dismissed as overly optimistic by
foreign donors considering investment in TB control in
Haiti.
We assumed that HIV seroprevalence would remain con-
stant over the next 20 years even though HIV seropreva-
lence has risen in most developing countries over the past
two decades. However if HIV seroprevalence did increase,
with a corresponding increased incidence of TB, societal
saving would be greater with DOTS (Figure 3), because of
improved case detection with corresponding reduction in
mortality of undiagnosed active TB in HIV infected. We
did not model the potential effect of large scale provision
of antiretroviral therapy (ART). This is just being intro-
duced in Haiti and other low income countries, so the
costs, efficacy, and population impact of ART are currently
unknown. Our assumption of unchanged drug resistance
may be incorrect. However, in sensitivity analysis, even
when the prevalence of drug resistance was doubled,
results were very similar. We also assumed no population
growth for Haiti, despite current annual growth of 1.4%
[23]. However, a larger population would simply mean
more new infections, and new active cases – with either
strategy. And, as with higher HIV sero-prevalence, DOTS
would be even more cost-saving relative to the status quo
strategy.
We have projected that DOTS expansion in Haiti could
prevent a large number of TB cases, and TB deaths, with
substantial resultant societal savings. But this would
require significant Haitian government investment –
which may be difficult to ensure, given current political
instability and the prospect of little payback after many
years. Given this, and the substantial potential humanitar-
ian, economic, and public health benefits, we conclude
that foreign donors should strongly consider investing in
DOTS expansion in Haiti.BMC Public Health 2006, 6:209 http://www.biomedcentral.com/1471-2458/6/209
Page 11 of 13
(page number not for citation purposes)
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
V. J. – Conception of project, data gathering, drafting
manuscript
W. M. – Data gathering and critical revisions of manu-
script
K. S. – Conception of project, data analysis, critical revi-
sions of manuscript
O. O. – Conception of project, data gathering, data analy-
sis, critical revisions of manuscript
G. B. – Conception of project, data analysis, critical revi-
sions of manuscript
F. G. – Conception of project, and critical revision of man-
uscript
D. M. – Conception of project, data gathering, data analy-
sis, drafting manuscript
Acknowledgements
We are grateful to many staff of the National TB Programme in Haiti, Sarah 
Hoibak for assistance in the health facility and patient costs questionnaire, 
Jason McKnight for assistance in data analysis, and Catherine Michaud for 
seemingly endless revisions of this manuscript.
Supported by a grant from the Rockefeller Foundation Drs. Schwartzman 
and Menzies are recipients of research career awards from the Fonds de 
Recherche en Santé du Québec. Dr. Barr is the recipient of a Robert Wood 
Johnson Generalist Physician Faculty Scholar Award.
References
1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione
MC, et al.: The growing burden of tuberculosis: global trends
and interactions with the HIV epidemic.  Arch Intern Med 2003,
163(9):1009-1021.
2. Kochi A: The global tuberculosis situation and the new con-
trol strategy of the World Health Organization.  Tuberc 1991,
72:1-6.
3. World Health Organization: Treatment of Tuberculosis: Guide-
lines for National Programmes.  Geneva Second 1997.
4. Murray CJL, Styblo K, Rouillon A: Tuberculosis in developing
countries: burden, intervention and cost.  Bull Int Union Against
Tuberculosis 1990, 65(1):2-20.
5. Suarez PG, Watt CJ, Alarcon E, Portocarrero J, Zavala D, Canales R,
et al.: The dynamics of tuberculosis in response to 10 years of
intensive control effort in Peru.  J Infect Dis 2001, 184:473-478.
6. Floyd K, Blanc L, Raviglione M, Lee JW: Resources required for
global tuberculosis control.  Science 2002, 295(5562):
2040-2041.
7. Sachs J: Macroeconomics and Health: Investigating in Health
for Economic Development.  World Health Organization 2001.
8. World Health Organization: Global Tuberculosis Control: Sur-
veillance, Planning, Financing.  In WHO Report Geneva, Switzer-
land; 2003. 
9. The World Bank Group. Haiti Data Profile. 12-8-2003   [http/
devdata.worldbank.org/external/CPPro
file.asp?CCODE=HTI&PTYPE=CP]
10. UNAIDS:  Joint United Nations Programme on HIV/AIDS.
2002 [http://www.unaids.org/EN/default.asp#].
11. Lee JW, Espinal M, Jaramillo E: Report of site visit to evaluate
DOTS expansion in Latin America.  World Health Organization,
editor 2002.
12. Pitchenik AE, Russell BW, Cleary T, Pejovic I, Cole C, Snider D Jr:
The prevalence of tuberculosis and drug resistance among
Haitians.  N Engl J Med 1982, 307(3):162-165.
13. Scalcini M, Carré G, Jean-Baptiste M, Hershfield E, Parker S, Wolfe J,
et al.: Antituberculosis drug resistance in Central Haiti.  Am
Rev Respir Dis 1990, 142:508-511.
14. Styblo K: The relationship between the risk of tuberculosis
infection and the risk of developing infectious tuberculosis.
Bull Int Union Tuberc 1985, 60(3–4):117-119.
15. Floyd K, Skeva J, Nyirenda T, Gausi F, Salaniponi F: Cost and cost-
effectiveness of increased community and primary care facil-
ity involvement in tuberculosis care in Lilongwe District,
Malawi.  Int J Tuberc Lung Dis 2003, 7(9 Suppl 1):S29-S37.
16. Floyd K, Wilkinson D, Gilks C: Comparison of cost effectiveness
of directly observed treatment (DOT) and conventionally
delivered treatment for tuberculosis: experience from rural
South Africa.  BMJ 1997, 315(7120):1407-1411.
17. Sherman LF, Fujiwara PI, Cook SV, Bazerman LB, Frieden TR: Patient
and health care system delays in the diagnosis and treatment
of tuberculosis.  Int J Tuberc Lung Dis 1999, 3(12):1088-1095.
18. Yamasaki-Nakagawa M, Ozasa K, Yamada N, Osuga K, Shimouchi A,
Ishikawa N, et al.: Gender diference in delays to diagnosis and
health care seeking behaviour in a rural area of Nepal.  Int J
Tuberc Lung Dis 2001, 5(1):24-31.
19. Wandwalo ER, Mørkve O: Delay in tuberculosis case-finding
and treatment in Mwanza, Tanzania.  Int J Tuberc Lung Dis 2000,
4(2):133-138.
20. Caminero Luna JA: Guia de la Tuberculosis para Medicos Espe-
cialistas.  In Union Internacional contra la Tuberculosis y Enfermedades
Respiratorias (UICTER), editor. 6432 Imprime en France, Imprimerie
Chirat; 2003.  Depot Legal 2003 No 6432
21. Gupta R, Cegielski JP, Espinal MA, Henkens M, Kim JY, Lambregts-van
Weezenbeek CSB, et al.: Increasing transparency in partner-
ships for health – introducing the Green Light Committee.
Tropical Medicine and International Health 2002, 7(2):970-976.
22. Suarez PG, Floyd K, Portocarrero J, Alarcon E, Rapiti E, Ramos G, et
al.: Feasibility and cost-effectiveness of standardised second-
line drug treatment for chronic tuberculosis patients: a
national cohort study in Peru.  Lancet 2002, 359(9322):
1980-1989.
23. CIA – The World Factbook. CIA – The World Factbook. 12-
9-2003   [http://www.cia.gov/cia/publications/factbook/geos/ha.html].
Washington, DC, Central Intelligence Agency – USA
24. Sutherland I: The evolution of clinical tuberculosis in adoles-
cents.  Tuberc 1966, 47:308.
25. Van Zwanenberg D: The Influence of the number of bacilli on
the development of tuberculous disease in children.  Am Rev
Respir Dis 1960, 82:31-44.
26. Ferebee SH: Controlled chemoprophylaxis trials in tuberculo-
sis.  Adv Tuberc Res 1969, 17:28-106.
27. Menzies D: Issues in the management of contacts of patients
with active pulmonary tuberculosis.  Can J Public Health 1997, 88
(3):197-201.
28. Comstock GW, Edwards LB, Livesay VT: Tuberculosis morbidity
in the US Navy: its distribution and decline.  Am Rev Respir Dis
1974, 110:572-580.
29. Nolan CM, Elarth AM: Tuberculosis in a cohort of Southeast
Asian refugees: A five-year surveillance study.  Am Rev Resp
Dis 1988, 137:805-809.
30. Cummings KC, Mohle-Boetani J, Royce SE, Chin DP: Movement of
tuberculosis patients and the failure to complete antituber-
culosis treatment.  Am J Respir Crit Care Med 1998, 157(4 Pt 1):
1249-1252.
31. Chee CBE, Boudville IC, Chan SP, Zee YK, Wang YT: Patient and
disease characteristics, and outcome of treatment default-
ers from the Singapore TB control unit – a one-year retro-
spective survey.  Int J Tuberc Lung Dis 2000, 4(6):496-503.BMC Public Health 2006, 6:209 http://www.biomedcentral.com/1471-2458/6/209
Page 12 of 13
(page number not for citation purposes)
32. Parthasarathy R, Prabhakar R, Somasundaram PR: A controlled clin-
ical trial of 3- and 5-month regimens in the treatment of spu-
tum-positive pulmonary tuberculosis in South India.  Am Rev
Respir Dis 1986, 134:27-33.
33. East African/British Medical Research Councils Study: Controlled
clinical trial of five short-course (4-month) chemotherapy
regimens in pulmonary tuberculosis: Second report of the
4th study.  Am Rev Respir Dis 1981, 123:165-170.
34. Singapore Tuberculosis Service/British Medical Research Council:
Long-term Follow-up of a clinical trial of six-month and four-
month regimens of chemotherapy in the treatment of pul-
monary tuberculosis.  Am Rev Respir Dis 1986, 133:779-783.
35. Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, Whitworth JA:
HIV-1 infection in rural Africa: is there a difference in
median time to AIDS and survival compared with that in
industrialized countries?  AIDS 2002, 16(4):597-603.
36. Wood R, Maartens G, Lombard CJ: Risk factors for developing
tuberculosis in HIV-1 – Infected adults from communities
with low or very high incidence of tuberculosis.  J Acquir
Immune Defic Syndr 2000, 23:75-80.
37. Murray J, Sonnenberg P, Shearer SC, Godgrey-Faussett P: Human
immunodeficiency virus and outcome of treatment for new
and recurrent pulmonary tuberculosis in African patients.
Am J Respir Crit Care Med 1999, 159:733-740.
38. Chaisson RE, Clermont HC, Hole EA, Cantave M, Johnson MP, Atkin-
son J, et al.: Six-month supervised intermittent tuberculosis
therapy in Haitian patients with and without HIV infection.
Am J Respir Crit Care Med 1996, 154:1034-1038.
39. Desvarieux M, Hyppolite PR, Johnson WD, Pape JW: A novel
approach to directly observed therapy for tuberculosis in an
HIV-endemic area.  Am J Public Health 2001, 91(1):138-141.
40. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J:
Accelerated course of human immunodeficiency virus infec-
tion after tuberculosis.  Am J Respir Crit Care Med 1995, 151:
129-135.
41. Connolly C, Reid , Davies G, Sturm W, McAdam K, Wilkinson D:
Relapse and mortality among HIV-infected and uninfected
patients with tuberculosis successfully treated with twice
weekly directly observed therapy in rural South Africa.  AIDS
1999, 13:1543-1547.
42. Beck-Sague C, Dooley SW, Hutton MD, Otten J, Breedan A, Craw-
ford JT, et al.: Hospital outbreak of multi-drug resistant Myco-
bacterium tuberculosis infections: Factors in transmission to
staff and HIV-infected patients.  JAMA 1992, 268:1280-1286.
43. Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM,
et al.: An outbreak of multi-drug resistant tuberculosis among
hospitalized patients with the acquired immunodeficiency
syndrome.  New Engl J Med 1992, 326(23):1514-1521.
44. Lopez AD, Salomon J, Ahmad O, Murray CJL, Mafat D: Life Tables
for 191 Countries: Data, Methods and Results.  Geneva,
World Health Organization (GPE Discussion Paper Series: No.9);
2000. 
45. Drummond MF, O'Brien B, Stoddart GL, Torrance GW: Methods
for the economic evaluation of health care programmes.
2nd edition. New York: Oxford University Press; 1997. 
46. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB: Recom-
mendations of the Panel on Cost-Effectiveness in Health and
Medicine.  JAMA 1996, 276(15):1253-1258.
47. Ainsworth M, Koda G, Lwihula G, Mujinja P, Over M, Semali I: Meas-
uring the Impact of Fatal Adult Illness in Sub-Saharan Africa
– An Annotated Household Questionnaire.  In LSMS Living
Standards Measurements Study Working Paper No.90 Washington, DC,
The World Bank; 1992. 
48. Vaca J, Peralta H, Gresely L, Cordova R, Kuffo D, Romero E, et al.:
DOTS implementation in a middle income country – Devel-
opment and evaluation of a novel approach.  Int J Tuberc Lung
Dis 2005, 9(5):521-527.
49. World Bank Website  2004 [http://www.worldbank.org/data/
countrydata/countrydata.html]. Access date: April 15, 2004
50. Global Drug Facility: First-Line tuberculosis drugs& formula-
tions currently supplied/to be supplied by the global TB drug
facility.  World Health Organization, editor 2003 [http://stoptb.org/gdf/
drugsupply/drugs_available.asp]. Access date: November 15, 2003
51. The World Bank Group: Achieving the MDG's and related out-
comes: A framework for monitoring policies and actions.
2004 [http://www.developmentgoals.org/].
52. Management of Tuberculosis: A guide for low income countries.
Fifth edition. International Union Against Tuberculosis and Lung Dis-
ease; 2000. 
53. Roos BR, van Cleeff MRA, Githui WA, Kivihya-Ndugga L, Odhiambo
JA, Kibuga DK, et al.:  Cost-effectiveness of the polymerase
chain reaction versus smear examination for the diagnosis of
tuberculosis in Kenya: a theoretical model.  Int J Tuber Lung Dis
1997, 2(3):235-241.
54. Suarez P: Government of Peru MoH.  In Tuberculosis en el Perú
Informe 2000 Lima, Peru; 2001. 
55. The effect of tuberculosis control in China.  Lancet 2004, 364(
9432):417-422.
56. Elzinga G, Raviglione MC, Maher D: Scale up: meeting targets in
global tuberculosis control.  Lancet 2004, 363(9411):814-819.
57. Borgdorff MW: Annual risk of tuberculous infection: time for
an update?  Bull World Health Organ 2002, 80(6):501-502.
58. Khatri GA, Frieden TR: Controlling Tuberculosis in India.  N Engl
J Med 2002, 347(18):1420-1425.
59. Burgess AL, Fitzgerald DW, Severe P, Joseph P, Noel E, Rastogi N, et
al.: Integration of tuberculosis screening at an HIV voluntary
counselling and testing centre in Haiti.  AIDS 2001, 15:
1875-1879.
60. Dasgupta K, Schwartzman K, Marchand R, Tannenbaum TN, Brassard
P, Menzies D: Comparison of cost effectiveness of tuberculosis
screening of close contacts and foreign-born populations.
Am J Respir Crit Care Med 2000, 162(6):2079-2086.
61. Comstock GM: How much isoniazid is needed for prevention
of tuberculosis in immunocompetent adults.  Int J Tuberc Lung
Dis 1999, 3(10):847-850.
62. Nolan CM, Aitken ML, Elarth AM, Anderson KM, Miller WT: Active
tuberculosis after isoniazid chemoprophylaxis of Southeast
Asian refugees.  Am Rev Respir Dis 1986, 133:431-436.
63. Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG: Worldwide
incidence of multidrug-resistant tuberculosis.  J Infect Dis 2002,
185(8):1197-1202.
64. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi
P, et al.: A trial of three regimens to prevent tuberculosis in
Ugandan adults infected with the human immunodeficiency
virus.  In N Engl J Med Volume 337. Issue 12 Uganda-Case Western
Reserve University Research Collaboration; 1997:801-808. 
65. Guelar A, Gatell JM, Verdejo J, Podzamczer D, Lozano L, Aznar E, et
al.: A prospective study of the risk of tuberculosis among
HIV-infected patients.  AIDS 1993, 7:1345-1349.
66. Grzybowski S, Barnett GD, Styblo K: Contacts of cases of active
pulmonary tuberculosis.  Bull IUAT 1975, 50:90-106.
67. Fischl MA, Uttamchandani RB, Daikos L, Poblete RB, Moreno JN,
Reyes RR, et al.: An outbreak of tuberculosis caused by multi-
ple-drug resistant tubercle bacilli among patients with HIV
infection.  Ann Intern Med 1992, 117:177-183.
68. Small P, Shafer R, Hopewell P: Exogenous reinfection with multi-
drug-resistant Mycobacterium tuberculosis in patients with
advanced HIV infection.  N Engl J Med 1993, 328:1137-1144.
69. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs
WR, et al.: An outbreak of tuberculosis with accelerated pro-
gression among persons infected with the human immuno-
deficiency virus.  New Engl J Med 1992, 326(4):231-235.
70. Stead WW: Management of health care workers after inad-
vertent exposure to tuberculosis: A guide for use of preven-
tive therapy.  Ann Intern Med 1995, 122:906-912.
71. Rieder HL: Epidemiologic basis of tuberculosis control.  First
edition. Paris, France, International Union Against Tuberculosis and
Lung Disease; 1999:1-162. 
72. Grzybowski S, Enarson DA: The fate of cases of pulmonary
tuberculosis under various treatment programmes.  Bull Int
Union Tuberc 1978, 53(2):70-74.
73. Horwitz O: Public health aspects of relapsing tuberculosis.  Am
Rev Respir Dis 1969, 99:183-193.
74. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA: A 62-
dose, 6-month therapy for pulmonary and extrapulmonary
tuberculosis. A twice-weekly, directly observed, and cost-
effective regimen.  Ann Intern Med 1990, 112(6):407-415.
75. Results at 5 years of a controlled comparison of a 6-month
and a standard 18-month regimen of chemotherapy for pul-
monary tuberculosis.  Am Rev Respir Dis 1977, 116(1):3-8.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Public Health 2006, 6:209 http://www.biomedcentral.com/1471-2458/6/209
Page 13 of 13
(page number not for citation purposes)
76. Somner AR: Short-course chemotherapy in pulmonary tuber-
culosis. A controlled trial by the British Thoracic Association
(third report).  Lancet 1980, 1(8179):1182-1183.
77. Controlled clinical trial comparing a 6-month and a 12-
month regimen in the treatment of pulmonary tuberculosis
in the Algerian Sahara. Algerian working group/British Med-
ical Research Council cooperative study.  Am Rev Respir Dis
1984, 129(6):921-928.
78. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A,
Chaisson R, et al.: Rifapentine and isoniazid once a week versus
rifampicin and isoniazid twice a week for treatment of drug-
susceptible pulmonary tuberculosis in HIV-negative
patients: a randomised clinical trial.  Lancet 2002, 360(9332):
528-534.
79. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB,
et al.: Standard short-course chemotherapy for drug-resist-
ant tuberculosis: treatment outcomes in 6 countries.  JAMA
2000, 283(19):2537-2545.
80. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcantara F, et al.:
Community-based therapy for multidrug-resistant tubercu-
losis in Lima, Peru.  N Engl J Med 2003, 348(2):119-128.
81. Deschamps MM, Fitzgerald DW, Pape JW, Johnson WD: HIV Infec-
tion in Haiti: Natural History and Disease Progression.  AIDS
2000, 14:2515-2521.
82. Malkin JE, Prazuck T, Simonnet F, Yameogo M, Rochereau A, Ayerour
J, et al.:  Tuberculosis and human immunodeficiency virus
infection in West Burkina Faso: clinical presentation and
clinical evolution.  Int J Tuberc Lung Dis 1997, 1(1):68-74.
83. Johnson JL, Okwera A, Vjecha MJ, Byekwaso F, Nakibali J, Nyole S, et
al.: Risk factors for relapse in human immunodeficiency virus
type 1 infected adults with pulmonary tuberculosis.  Int J
Tuberc Lung Dis 1997, 1(5):446-453.
84. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-
Faussett P: HIV-1 and recurrence, relapse, and reinfection of
tuberculosis after cure: a cohort study in South African
mineworkers.  Lancet 2001, 358(9294):1687-1693.
85. Pulido F, Peña JM, Rubio R, Moreno S, González J, Guijarro C, et al.:
Relapse of tuberculosis after treatment in human immuno-
deficiency virus-infected patients.  Arch Intern Med 1997, 157:
227-231.
86. Deas J: Haiti's Response to Tuberculosis and Malaria.  Applica-
tion to the Global Fund to Fight AIDS TaM, editor 2002.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2458/6/209/pre
pub